Figure 2 Dysfunction of GLP-1 and Diseases GLP-1 and AD AD is the most common neurodegenerative disease with an incurable cognitive impairment, but recently hope is proposed due to the development of Biogens monoclonal antibody drug aducanumab (ADU) in the USA
Many were given the golden ticket of a prescription by their doctors, but found themselves frustrated after calling dozens of pharmacies and being unable to redeem it for the brand name product
Landon R, Gueguen V, Petite H, Letourneur D, Pavon-Djavid G, Anagnostou F (2020) Impact of astaxanthin on diabetes pathogenesis and chronic complications
Doi T, Matsubara N, Kawai A, Naka N, Takahashi S, Uemura H, et al
Semaglutide therapy is generally a well-tolerated procedure, with minimal side effects that typically subside within a few days
Arterial stiffness as surrogate end point: Needed clinical trials